In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria | Zendy

Laure Stapert | Zendy; Cindy L. Wolfe | Zendy; Dean Shinabarger | Zendy; Andrea Marra | Zendy; Chris M. Pillar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria

Author(s) -

Laure Stapert,

Cindy L. Wolfe,

Dean Shinabarger,

Andrea Marra,

Chris M. Pillar

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00047-18

Subject(s) - anaerobic bacteria , bacteroides fragilis , clostridium perfringens , microbiology and biotechnology , peptostreptococcus , bacteroides , prevotella , clostridium , tigecycline , anaerobic exercise , biology , medicine , chemistry , bacteria , antimicrobial , antibiotics , physiology , genetics

Omadacycline (OMC), a broad-spectrum aminomethylcycline, has shown clinical efficacy in anaerobic acute bacterial skin and skin structure infections (ABSSSI) and in animal models of intra-abdominal anaerobic infections. Here, the in vitro activity of OMC against clinically relevant anaerobes was similar to that of tigecycline, with MIC 90 values of 1 to 8 μg/ml against Bacteroides spp., 0.5 μg/ml against Clostridium difficile , Prevotella spp., and Porphyromonas asaccharolytica , 1 μg/ml against Peptostreptococcus spp., and 16 μg/ml against Clostridium perfringens .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research